Azam Ghafoor, M.D.
National Cancer Institute (NCI)
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Azam Ghafoor, M.D. as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:45 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT04027946 · LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC)National Cancer Institute (NCI) · terminated · Lung Cancer, Non-Small Cell Lung Cancer, Adenocarcinoma of Lung · principal investigator
- Ph2NCT02759835 · Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With OsimertinibNational Cancer Institute (NCI) · completed · Lung Adenocarcinoma, Lung Neoplasms · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:45 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in non-small cell lung cancer.